12.69 USD
+0.00
0.00%
At close Jan 10, 4:00 PM EST
After hours
12.85
+0.16
1.26%
1 day
0.00%
5 days
-5.93%
1 month
-4.59%
3 months
3.51%
6 months
11.32%
Year to date
-3.35%
1 year
60.03%
5 years
34.86%
10 years
-2.68%
 

About: Barclays is a universal bank headquartered in the United Kingdom. It operates via five principal segments; UK (retail), UK corporate bank, private bank and wealth management, investment bank, and us consumer bank. In its UK segment, the bank provides current accounts, mortgages, savings and investment management services, credit cards, and business banking services to retail clients and small and medium-size enterprises. The international segment includes a corporate bank offering banking solutions to large corporates, a bulge-bracket global investment bank, and a credit card and payments business.

Employees: 92,400

0
Funds holding %
of 6,814 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

74% more repeat investments, than reductions

Existing positions increased: 160 | Existing positions reduced: 92

22% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 41

9% more capital invested

Capital invested by funds: $2.23B [Q2] → $2.44B (+$211M) [Q3]

2% more funds holding

Funds holding: 348 [Q2] → 354 (+6) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0.1% less ownership

Funds ownership: 1.4% [Q2] → 1.3% (-0.1%) [Q3]

9% less call options, than puts

Call options by funds: $77.9M | Put options by funds: $85.6M

Research analyst outlook

We haven’t received any recent analyst ratings for BCS.

Financial journalist opinion

Based on 16 articles about BCS published over the past 30 days

Neutral
CNBC International TV
3 days ago
Market volatility expected until U.S. inauguration day, Barclays says
Emmanuel Cau, head of European equity strategy at Barclays, weighs in on the outlook for European stocks in 2025.
Market volatility expected until U.S. inauguration day, Barclays says
Positive
Seeking Alpha
6 days ago
Barclays: Set To Soar To Greater Heights
Barclays had a stellar 2024, rising over 70%, driven by a rebound in investment banking activity, strong cost controls, and higher NIMs despite falling rates thanks to structural hedges. Management's ambitious targets for income growth through to FY26 haven't been priced in, with an improved cost-to-income ratio, and plans for giant shareholder returns. Unlike some other UK banks, BCS is uniquely positioned to benefit from both sides of the rate environment due to its structural hedges and IB division, offering multiple growth catalysts.
Barclays: Set To Soar To Greater Heights
Negative
New York Post
2 weeks ago
Barclays fires over a dozen bankers, traders before Christmas — without giving them bonuses: sources
The scrooges at Barclays canned 15 Wall Street workers out of the roughly 50 it pink-slipped last month, two sources with close knowledge of the situation said.
Barclays fires over a dozen bankers, traders before Christmas — without giving them bonuses: sources
Positive
Forbes
2 weeks ago
What Drove The 70% Surge In Barclays Stock This Year?
Barclays stock (NYSE: BCS) has gained about 70% year-to-date, as compared to the 25% rise in the S&P500 over the same period. In contrast, Barclays' peer Bank of America (NYSE: BAC) is up 35% year-to-date.
What Drove The 70% Surge In Barclays Stock This Year?
Neutral
CNBC Television
2 weeks ago
CagriSema still keeps the Novo Nordisk story in tact, says Barclays' Emily Field
Emily Field, Barclays head of European pharmaceutical research, joins 'Squawk Box' to discuss the state of the weight loss drug market, disappointing trial results of Novo Nordisk's experimental CagriSema weight loss drug, and more.
CagriSema still keeps the Novo Nordisk story in tact, says Barclays' Emily Field
Positive
Seeking Alpha
3 weeks ago
Barclays: Still Trading At 0.6x 2026 Book Value
Barclays remains a high-conviction pick, outperforming peers in 2024, trading at ~0.6x 2026 TBV despite a 70% YTD increase. The bank targets a +12% RoTE by 2026, focusing on high-return UK segments and cost efficiency, driving current outperformance. Analysts projections expect Barclays to meet cost-income targets but fall short on RoTE due to lower revenue growth; current valuation reflects a discount to U.S. peers.
Barclays: Still Trading At 0.6x 2026 Book Value
Neutral
Bloomberg Markets and Finance
3 weeks ago
Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says
Emily Field, Barclays' head of European pharmaceutical research, reacts to the selloff in Novo Nordisk's shares after its experimental obesity shot CagriSema failed to meet expectations. She speaks on "Bloomberg Open Interest.
Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says
Positive
Proactive Investors
3 weeks ago
NatWest, Barclays cuts followed by further drop in mortgage rates
Mortgage rates edged lower once again this week, meaning prospective buyers enjoyed a straight month of declining borrowing costs. According to Moneyfacts, the average rate of a two-year fixed mortgage fell from 5.4685% on Monday to 5.4603% as of Friday.
NatWest, Barclays cuts followed by further drop in mortgage rates
Neutral
CNBC International TV
3 weeks ago
Barclays: Bank of Japan needs to justify normalizing rates
Naohiko Baba of Barclays reacts to the Bank of Japan's latest decision to hold rates steady, and explains why he thinks the central bank has room for two rate hike in 2025.
Barclays: Bank of Japan needs to justify normalizing rates
Negative
CNBC International TV
3 weeks ago
The Fed is flip-flopping and their message was too hawkish in the near-term: Barclays
Ajay Rajadhyaksha of Barclays says that the inconsistency of the Fed contributed to the negative reaction of the markets and that the Fed could change tacks again as early as January when the December payrolls print is out.
The Fed is flip-flopping and their message was too hawkish in the near-term: Barclays
Charts implemented using Lightweight Charts™